FDA: no CBD does not cure illness

FDA: Curaleaf claims to have developed that can treat many diseases such as cancer, Alzheimer's, Parkinson's, depression, opioid withdrawal syndrome, chronic pain, anxiety, post-traumatic stress disorder, attention-deficit/hyperactivity disorder (ADHD).

According to the company, it has products that are supposed to treat stress, and diabetes in cats and dogs. (This product comes in bacon and salmon flavors.)

The only ingredient responsible for all of the above is a cannabis-derived cannabis (CBD).

FDA

Unfortunately, these claims are not supported by evidence.

This week, the Food and Drug Administration (FDA) he said that he sent Curaleaf a letter of formal notice for the illegal sale of unauthorized medicinal products and their disposal as therapeutic products.

These claims that CBD-containing products can cure serious illnesses and conditions "could endanger patients and consumers by leading them to delay significant medical care," said Fed Commissioner Ned Sharpless.

In addition, there are many unanswered questions from science, about , the efficacy and quality of unapproved products containing CBD.

Cloudy the legal landscape

The CBD ingredient is a relatively safe ingredient in cannabis that seems to have no addictive risks and does not put you in a "high" state.

In addition, it has been shown to be able to have sedative action, but also to help with seizures.

Last June, the FDA approved Epidiolex as the first CBD-based drug to help two rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients s from two years and older. However, the substance cannot be called therapeutic since it does not cure the cause but fights the symptom. Soothing yes, healing no.

At the time of FDA approval, the Drug Enforcement Department (DEA) considered the CBD a Program I drug and was in the same category as cannabis, heroin and LSD. With the approval of Epidiolex by the FDA, it was removed from the DEA list.

However, there still appear to be gaps in the legal framework.

The FDA says it will set up a "high-level internal working group to investigate the various types of CBD products to be legally marketed."

The organization seeks not only to collect scientific data on the effects of CBD but also to establish appropriate regulations for safety, marketing, labeling and quality control.

As for Curaleaf, the company said it "strives to have the highest standards of quality and compliance and will work with the FDA to of all the matters mentioned in the letter."

He has 15 business days to do it.

__________________________

iGuRu.gr The Best Technology Site in Greecefgns

every publication, directly to your inbox

Join the 2.100 registrants.

Written by giorgos

George still wonders what he's doing here ...

Leave a reply

Your email address is not published. Required fields are mentioned with *

Your message will not be published if:
1. Contains insulting, defamatory, racist, offensive or inappropriate comments.
2. Causes harm to minors.
3. It interferes with the privacy and individual and social rights of other users.
4. Advertises products or services or websites.
5. Contains personal information (address, phone, etc.).